MIAMI, FLORIDA – Researchers conducting a Phase 2 clinical trial at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine say a new combination of antibody therapies produced a ‘surprisingly high’ response rate in patients with high-risk follicular lymphoma, a type of non-Hodgkin lymphoma. Based on...
Latest News
According to the results of a phase 1/2 study, combination therapy with the mTOR inhibitor temsirolimus and the immunomodulatory agent lenalidomide (TEM/LEN) was feasible and demonstrated activity in heavily pretreated lymphomas, including relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL). The open-label, multicenter, phase 1/2 study (ClinicalTrials.gov identifier: NCT01076543) accrued patients with R/R...
Birmingham, England – Children who develop neuroblastomas, a rare form of cancer which develops in nerve cells, may benefit from receiving certain anti-tumour drugs as well as chemotherapy, a new trial has found. The results of the BEACON trial conducted by the Cancer Research UK Clinical Trials Unit at the...
Copper has been clinically improving the lives of people since about 1500 BCE, when an Egyptian physician first recorded its use as a treatment for inflammation. Some 35 centuries later, researchers at Johns Hopkins Medicine and Italy’s Catholic University of the Sacred Heart medical school have provided solid evidence that...
Adding liposomal irinotecan (LI) to fluorouracil and leucovorin (FL) significantly improved survival in patients with previously treated, metastatic biliary tract cancer, according to research published in The Lancet Oncology. In the phase 2b NIFTY trial (ClinicalTrials.gov Identifier: NCT03524508), researchers compared second-line LI plus FL with FL alone in patients with metastatic biliary...
About one in 100 children has a common brain disorder called Chiari 1 malformation, but most of the time such children grow up normally and no one suspects a problem. But in about one in 10 of those children, the condition causes headaches, neck pain, hearing, vision and balance disturbances,...
Göteborg, Sweden – Alzheimer’s disease (AD) is associated with damaging protein aggregates in the brain, with β-amyloid (Aβ) aggregates called plaques being the key pathology. Entresto (sacubitril/valsartan) is a combined neprilysin inhibitor and angiotensin receptor blocker, approved for the treatment of heart failure. Concerns were raised by the FDA that...
Amanda Judice was doing what many college students like to do on semester break – enjoying a winter ski trip. Then, her world turned upside down, and not from a tumble on the slopes. The 20-year-old product of Fatima and St. Thomas More, a Delta Delta Delta sorority member at...
Clinicohematologic complete response (CHCR) rates demonstrated that pegylated interferon alpha-2a was the most effective treatment for patients with essential thrombocythemia (ET), according to results of a real-world comparison with hydroxyurea and ruxolitinib in patients with myeloproliferative neoplasms (MPNs) reported in Hematology. The Philadelphia chromosome-negative MPNs (polycythemia vera [PV], ET, and myelofibrosis...
BOSTON – Compass Therapeutics, Inc. (OTC:CMPX) provided an update on the clinical development of CTX-009 (also known as ABL001), a dual anti-angiogenic bispecific antibody targeting DLL4 and VEGF-A. A Phase 2a study for CTX-009 in combination with paclitaxel was initiated by Handok Pharmaceuticals, Inc. (KOSDAQ: 002390) in Q1 2021 in...